CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is  a   biotech which has been effective diligently but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix. In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terminology of […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective diligently but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn's inventories of leronlimab are actually building up, whether they'll ever be being used is actually an open question.


While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past several shares of mine. The 1st CytoDyn article of mine, "CytoDyn: What To Do When It's Too Good to be able to Be True?", set away what follows prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such a highly promotional image in the Uptick Newswire job interview which I came away with a poor impression of the business.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, however, the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back during 2012, announced as follows:

CytoDyn Inc.... has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the therapy and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today's transaction of $3.5 million transfers ownership of this technology and linked intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of majority drug substance.... milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) along with the very first brand new drug program endorsement ($five million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that point in time, CytoDyn's helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It's done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it has this single remedy and a "broad pipeline of indications" as it places it. I call certain pipelines, "pipedots." In CytoDyn's case it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an active business with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple publications in addition to multiple delivering presentations.

Could all this be smoke and mirrors? That is a question I've been asking myself from the very start of the interest of mine in this particular company. Judging by way of the multiples of thousands of several comments on listings accessible via Seeking Alpha's CytoDyn Summary page, I'm far from alone in this question.

CytoDyn is a classic battleground, or maybe some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *